Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ctp-543 Phosphate
2. C-21543 Phosphate
3. D8-ruxolitinib Phosphate
4. D8- Ruxolitinib Phosphate
5. 8vj43s4lcm
6. Deuruxolitinib Phosphate [usan]
7. 2147706-60-1
8. Deuruxolitinib Phosphate (usan)
9. (3r)-3-(2,2,3,3,4,4,5,5-d8)cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Phosphate (1:1)
10. Leqselvi (tn)
11. Unii-8vj43s4lcm
12. Chembl4594382
13. D11867
14. 1h-pyrazole-1-propanenitrile, .beta.-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-, Phosphate
15. 1h-pyrazole-1-propanenitrile, Beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7hpyrrolo(2,3-d)pyrimidin-4-yl)-, (betar)-, Phosphate (1:1)
Molecular Weight | 412.4 g/mol |
---|---|
Molecular Formula | C17H21N6O4P |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 4 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 161 |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 503 |
Isotope Atom Count | 8 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...
Details:
Leqselvi (deuruxolitinib phosphate) is a JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata in adults.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: Leqselvi
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2024
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sun Pharma's drug to treat alopecia areata gets USFDA nod
Details : Leqselvi (deuruxolitinib phosphate) is a JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata in adults.
Product Name : Leqselvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2024
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, which is investigated for the treatmet of moderate to severe alopecia areata.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: Leqselvi
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sun Pharma Announces US FDA Filing Acceptance of New Drug Application (NDA) For Deuruxolitinib
Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, which is investigated for the treatmet of moderate to severe alopecia areata.
Product Name : Leqselvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2023
Details:
Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Dermatology Portfolio.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: $576.0 million Upfront Cash: $576.0 million
Deal Type: Acquisition June 03, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : $576.0 million
Deal Type : Acquisition
Sun Pharma Completes Acquisition of Concert Pharmaceuticals
Details : Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Der...
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : $576.0 million
June 03, 2023
Details:
Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: $15.0 million
Deal Type: Licensing Agreement May 12, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
Details : Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AG...
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
May 12, 2023
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2023
Details:
Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: $576.0 million Upfront Cash: $576.0 million
Deal Type: Acquisition January 19, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : $576.0 million
Deal Type : Acquisition
Details : Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in lat...
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : $576.0 million
January 19, 2023
Details:
Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2022
Details:
Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Terran Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 03, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Terran Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
Details : Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 03, 2022
Details:
The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp ...
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2022
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients...
Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2022
RLD : Yes
TE Code :
Brand Name : LEQSELVI
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 8MG BASE
Approval Date : 2024-07-25
Application Number : 217900
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies
Patents & EXCLUSIVITIES
Patent Expiration Date : 2044-05-10
US Patent Number : 12247034
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 217900
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2044-05-10
Patent Expiration Date : 2041-05-21
US Patent Number : 11919907
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 217900
Patent Use Code : U-3976
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2041-05-21
Patent Expiration Date : 2037-05-04
US Patent Number : 10561659
Drug Substance Claim :
Drug Product Claim :
Application Number : 217900
Patent Use Code : U-3976
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-05-04
Patent Expiration Date : 2037-05-04
US Patent Number : 12076323
Drug Substance Claim :
Drug Product Claim :
Application Number : 217900
Patent Use Code : U-3976
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-05-04
Exclusivity Code : NCE
Exclusivity Expiration Date : 2029-07-25
Application Number : 217900
Product Number : 1
Exclusivity Details :
ABOUT THIS PAGE